Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217101 | 1.00 | TACR1 (0.71) | TACR1KCNH2NR1I2 | |
| SCHEMBL5217091 | 1.00 | TACR1 (0.71) | TACR1KCNH2NR1I2 | |
| SCHEMBL5024860 | 0.89 | TACR1 (0.66) | TACR1KCNH2 | |
| SCHEMBL4461906 | 0.89 | TACR1 (0.66) | TACR1KCNH2 | |
| SCHEMBL3476484 | 0.85 | TACR1 (0.59) | TACR1KCNH2 | |
| SCHEMBL13677484 | 0.84 | TACR1 (0.77) | TACR1KCNH2NR1I2 | |
| SCHEMBL13677482 | 0.84 | TACR1 (0.77) | TACR1KCNH2NR1I2 | |
| SCHEMBL4689319 | 0.83 | TACR1 (0.55) | TACR1KCNH2NR1I2 | |
| SCHEMBL6616379 | 0.83 | TACR1 (0.55) | TACR1KCNH2NR1I2 | |
| SCHEMBL6353098 | 0.83 | TACR1 (0.55) | TACR1KCNH2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937264-B1 | COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE | MERCK SHARP & DOHME (US) | 2011-06-08 | — | — | EP | disclosed |
| US-7893091-B2 | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence | MERCK SHARP & DOHME CORP. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090270406-A1 | Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | disclosed |
| EP-1322596-B1 | ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-08-15 | — | — | EP | disclosed |
| US-7196113-B2 | Lactam tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20050282886-A1 | Lactam tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. | 2005-12-22 | — | — | US | disclosed |
| US-6479518-B2 | PSYCHOLOGICAL DISORDERS | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020042431-A1 | Zwitterionic tachykinin receptor antagonists | MERCK & CO., INC. | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042431-A1 | Zwitterionic tachykinin receptor antagonists | NPY5R, NPY1R, NPY2R | TACR1 11/4885KCNH2 263/4885NR1I2 1812/4885 |
| US-20090270406-A1 | Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence | MME, UTS2R, BPHL | TACR1 7/4885KCNH2 1764/4885NR1I2 2118/4885 |
| US-20050282886-A1 | Lactam tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885KCNH2 254/4885NR1I2 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.